化合物和化疗剂在恶性黑色素瘤中差异调节P2X受体亚型
1Department of Medical Laboratory Techniques, Ataturk Vocational School of Health Services, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey. serkansen07@gmail.com.
Purinergic signalling
|March 12, 2026
概括
这项研究揭示了黑色素瘤细胞是如何形成的.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 黑色素瘤是一种具有高转移潜力的侵袭性癌症,并且对治疗有抗性.
- 纯能P2X受体,特别是P2X7,涉及黑色素瘤细胞增殖,亡和侵袭.
- 治疗剂对P2X受体的转录调节并未得到充分理解.
研究的目的:
- 研究G361黑色素瘤细胞中所有七种P2X受体亚型 (P2XR1-7) 的转录调制.
- 评估化合物 (克尔塞丁,网红酸,白醇) 和化疗剂 (帕克利塔克塞尔,苏尼提尼布) 对P2X受体基因表达的影响.
主要方法:
- 用MTT测定来评估细胞活力.
- 使用非线性回归分析确定了半最大抑制度 (IC50).
- 使用定量实时PCR (qPCR) 来分析P2X受体亚型mRNA水平.
主要成果:
- 化疗药物 (帕克利塔塞尔,苏尼提尼布) 显示出强烈的细胞毒性,而化合物则具有中度的抗增殖作用.
- qPCR揭示了不同的转录反应:奎尔塞丁上调了多个P2X亚型,视网酸部分抑制了它们,而白醇选择性地降低了它们.
- 化疗药物通常可以提高P2XR4,P2XR5和P2XR7mRNA水平.
结论:
- P2X受体基因通过天然和合成化合物在转录上被差异调节.
- 这项研究为了解黑色素瘤中的P2X受体反应提供了一个转录框架.
- 特定的P2X受体亚型被确定为黑色素瘤治疗中进一步功能研究的候选者.
相关概念视频
Interactions Between Signaling Pathways
7.7K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.7K
Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Mitogens and the Cell Cycle
8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
715
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
715


